Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy

This is a prospective, single-arm, single-center exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of a triplet regimen-becotatug vedotin combined with anti-PD-1 and S-1-in patients with EGFR-positive advanced pancreatic cancer who have failed at least one line of standard systemic therapy. Pancreatic cancer is one of the most lethal malignancies, and patients who progress after first-line treatment have very limited effective options. The study plans to enroll 27 participants aged 18 years or older with histopathologically confirmed pancreatic cancer

Trial Details

NCT ID
NCT07892573
Phase
NA
Sponsor
Ningbo Medical Center Lihuili Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Becotatug Vedotin
  • Anti-PD-1 antibody
  • S-1
Locations (sample)
  • Ningbo, Zhejiang, China|29.87819,121.54945

Key Eligibility Criteria

  • Understands the study procedures and content and voluntarily signs written informed consent.
  • Age: 18 years or older.
  • Histopathologically confirmed pancreatic cancer.
  • The participant must have evidence of recurrence or metastasis, or have been assessed as not amenable to complete surgical resection, and must have…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →